UNSPSC 51162034: Guaifenesin/theophylline

This classification denotes a combination drug defined by the U.S. Department of Veterans Affairs in its (VA's) National Drug File (NDF), which falls under VA Drug Class RE109. This VA Drug Class (RE109) classifies this compound as belonging to the group ANTIASTHMA, OTHER.

UNSPSC 51162034 Guaifenesin/theophylline is a Commodity code, but the recent state and local opportunities tagged under it diverge significantly from the pharmaceutical-compound scope the code name suggests. The solicitations show state and local governments actually buying a much broader range of pharmacy and pharmaceutical services: naloxone and drug deactivation systems for public health responses, on-site employee pharmacy services, direct-to-manufacturer prescription fulfillment programs, and multi-source generic pharmaceuticals and over-the-counter products through cooperative purchasing. The actual procurement activity reflects operational pharmacy management and supply chain functions rather than single-ingredient formulations. Issuing bodies include county health departments (Seminole County, Florida), county government employee health plans (Hall County, Georgia), state health agencies (Texas Health and Human Services Commission), and state-led cooperative purchasing alliances (Minnesota Multistate Cooperative Purchasing Alliance, serving multiple states including Oregon). The mix spans health departments, county personnel services, and state agencies managing pharmacy benefit programs for employees and public health populations.

Geographic activity clusters in Florida and Georgia in recent months, with broader participation through the Minnesota cooperative purchasing alliance covering multiple states. Representative opportunities include Seminole County's IFB for 1,900 units of naloxone and 800 safe drug deactivation systems annually with a July 26, 2023 response deadline; Hall County's RFQ/P #47-010 for on-site pharmacy services at the Family Health Center Clinic in Gainesville, Georgia, due June 4, 2026, with scoring weighted 80 percent technical qualifications and 20 percent cost; Texas HHS Commission's RFI for direct-to-manufacturer prescription capabilities, posted April 3, 2026; and Minnesota's MMCAP cooperative RFP for generic multi-source pharmaceuticals and OTC products through authorized wholesalers, due March 26, 2026, with awards effective July 1, 2026.